Sciatica Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Sciatica market is segmented by Type (Acute, Chronic and Others), Pharmacological Therapies (Non-Steroidal anti inflammatory drug (NSAIDs), Steroids, Antidepressants, Painkillers and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Sciatica Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 9.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Sciatica market is projected to register a CAGR of 9.5% during the forecast period (2022 – 2027).

With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on the musculoskeletal system too. Low back pain is one of the most common symptoms for which patients seek medical evaluation. A study published in the Journal of Pain Research in 2021 showed that after hospital discharge, 27.3% of post-COVID-19 individuals reported joint pain and 21.7% chest pain. Again, it was highlighted that four weeks after discharge from the hospital, 10–20% of patients treated in the ward suffered from myalgia, although the percentage increased to up 30% in those who needed intensive care unit (ICU) hospitalization. As per an article by Dr. Mehul Garala 2020, it is said that 80% of the population will get low back pain at some point in life, and it also has a high recurrence rate. The pain does not always have to be related to physical activity, such as lifting, and can occur spontaneously, such as when waking up in the morning. Fortunately, the majority of low back pain episodes can resolve over time.

Certain factors that are driving the market growth include the high recurrence rate of sciatica patients, which proves to be positive upfront for the sciatica market and helps patients to try new interventions. Sciatica is likely to recur if the spinal disc that contributed to Sciatica is severely damaged. The more damaged the disc, the more likely it is to re-herniate and causes Sciatica again. Also, if the patient continues to work in a high-physical stress environment, the risk of recurrence increases. For people with persistent severe symptoms that don’t respond to analgesics or improve with activity modification, other treatment options include taking oral steroids or receiving epidural steroid injections — injections into the epidural space around the spinal cord. In a study published in the National Library of Medicine in 2022, patients with chronic pain (more than six months) have a poorer outcome following surgery than patients with acute pain (less than six months). Some studies reported a cure rate of more than 75%, but other studies report cure rates of less than 50%. There are several newer orthopedic procedures to manage Sciatica, and all report success rates of 70% and above in the short term. Therefore, people are expected to try new treatment approaches and hence driving the market positively.

Any condition that may structurally impact or compress the sciatic nerve may cause sciatica symptoms. The most common cause of Sciatica is a herniated or bulging lumbar intervertebral disc. In the elderly population, lumbar spinal stenosis may cause these symptoms as well. Spondylolisthesis or a relative misalignment of one vertebra relative to another may also result in sciatic symptoms. Additionally, lumbar or pelvic muscular spasm and/or inflammation may impinge a lumbar or sacral nerve root causing sciatic symptoms. A number of environmental and inherent factors thought to influence the development of Sciatica have been studied, including gender, body habitus, parity, age, genetic factors, occupation, and environmental factors. According to Mayo Clinic, in the United States, 80% of the population will have low back pain in their lifetime.

Thus, the increasing burden of Sciatica is leading to increasing demand for its treatment, as it is one of the most common conditions leading to chronic pain, thereby contributing to the market growth.

Scope of the Report

As per the scope of this report, Sciatica refers to pain that radiates along the path of the sciatic nerve, which branches from the lower back through your hips and buttocks and down each leg. Typically, Sciatica affects only one side of your body. The Sciatica market is segmented by Type (Acute, Chronic, and Others), Pharmacological Therapies (Non-Steroidal anti inflammatory drugs (NSAIDs), Steroids, Antidepressants, Painkillers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Type
Acute Sciatica
Chronic Sciatica
By Pharmacological Therapies
Non-Steroidal anti inflammatory drug (NSAIDs)
North America
Middle-East and Africa
South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Non-Steroidal anti inflammatory drug Segment is Expected to Hold a Major Market Share in the Sciatica Market

The Non-Steroidal anti-inflammatory drug segment occupies a major share of the market over the forecast period (2022 - 2027). The main anti‐inflammatory, antipyretic, and analgesic effect of NSAIDs is based on the suppression of the cyclooxygenase (COX)‐1 and COX‐2 enzymes. By blocking the COX enzymes, vasodilation is reduced and inflammation relieved.

Non-steroidal anti‐inflammatory drugs (NSAIDs) are one of the most frequently prescribed drugs for the treatment of sciatica. The products are getting approvals and hence, creating lucrative opportunities in the market. As per, 2022, pain killers stop the production of these cells, and the brain stops signaling that there is pain somewhere in the body. Pain killers and anti-inflammatory medicines are the most effective medicines that make up the most numerous group of drugs. Most commonly, antirheumatics (painkillers) are used to treat pain, fever, muscle pain, and other musculoskeletal disorders. Doctors recommend low-dose medications that can be purchased over the counter, such as Ibuprofen or Tylenol. The over-the-counter NSAIDs are meant to provide pain relief. Prescription NSAIDs may be necessary for pain relief if over-the-counter drugs are ineffective.


North America is Expected to Hold a Significant Share in the Market and Expected to do same in the Forecast Period (2022 - 2027).

The United States is the most affected country across the world, as there are higher numbers of patients suffering from Sciatica and higher in the North American region as the patient population is increasing compared to other countries.

North America is expected to hold a major market share in the global Sciatica market due to the rise in the geriatric population and increasing prevalence of lower back pain in this region. As per a study published by National Center for Health Statistics, in 2021, around 39% of adults in the United States stated they had experienced back pain within the past three months. A greater number of orthopedic procedures due to greater healthcare penetration in the United States and Canada drives the sciatica market. The high concentration of the major hospitals in the developed countries of this region, coupled with good reimbursement rates, is adding fuel to the market growth. Moreover, the large share of surgical procedures, especially sciatica treatment, in the returns of hospitals favors the market. Back pain is one of the most common types of pain among adults in the United States. Such pain can be caused by strained muscles or ligaments, excess weight, poor posture, psychological problems, or everyday activities. As per the Centers for Disease Control and Prevention, in the United States overall, nearly three in five adults (58.9%) experienced the pain of any kind in the past three months of 2019. Among adults, 39.0% experienced back pain, 36.5% experienced lower limb pain, and 30.7% experienced upper limb pain. The prevalence of pain experienced at each of these locations increased with age and was highest among adults aged 65 and over. The prevalence of pain at each of these locations was lowest among men and non-Hispanic Asian adults. Finally, the percentage of adults who experienced back, lower limb, and upper limb pain decreased with increasing family income.

Moreover, high expenditure on healthcare, especially in the United States and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional market to a large extent. ​

Sciatica Market

Competitive Landscape

The Sciatica market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Sorrento Therapeutics, SpineThera, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon life Science and others.

Recent Development

  • In March 2022, Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced final results for SP-102 (SEMDEXA) efficacy and safety from its pivotal Phase III clinical trial program for Sciatica pain management. SP-102 (SEMDEXA) demonstrated pain relief that continued through 12 weeks.
  • In December 2021, The United States Food and Drug Administration (FDA) granted Fast Track designation to SP-102 (injectable dexamethasone sodium phosphate viscous gel) for the treatment of lumbosacral radicular pain or sciatica.

Table of Contents


    1. 1.1 Study Assumptions & Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased public awareness and High survival rate of sciatica

      2. 4.2.2 Risk factors and increasing elderly population

    3. 4.3 Market Restraints

      1. 4.3.1 No single or definitive diagnostic criteria available

      2. 4.3.2 Several off-label drugs and physical therapy in market

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Acute Sciatica

      2. 5.1.2 Chronic Sciatica

      3. 5.1.3 Others

    2. 5.2 By Pharmacological Therapies

      1. 5.2.1 Non-Steroidal anti inflammatory drug (NSAIDs)

      2. 5.2.2 Steroids

      3. 5.2.3 Antidepressants

      4. 5.2.4 Painkillers

      5. 5.2.5 Others

    3. 5.3 Geography

      1. 5.3.1 North America

      2. 5.3.2 Europe

      3. 5.3.3 Asia-Pacific

      4. 5.3.4 Middle-East and Africa

      5. 5.3.5 South America


    1. 6.1 Company Profiles

      1. 6.1.1 Sorrento Therapeutics

      2. 6.1.2 SpineThera

      3. 6.1.3 Eliem Therapeutics

      4. 6.1.4 Scilex Holding

      5. 6.1.5 Sinfonia Biotherapeutics

      6. 6.1.6 Seikagaku Corporation

      7. 6.1.7 Kolon life Science

      8. 6.1.8 Vita Sciences

      9. 6.1.9 Aurobindo Pharma

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Sciatica Market market is studied from 2019 - 2027.

The Global Sciatica Market is growing at a CAGR of 9.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Sorrento Therapeutics, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics, Vita Science are the major companies operating in Global Sciatica Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!